Preferred Label : Amivantamab and Recombinant Human Hyaluronidase;
NCIt synonyms : Amivantamab and Hyaluronidase; Amivantamab Plus Recombinant Human Hyaluronidase; Amivantamab Recombinant Human Hyaluronidase; Amivantamab with Recombinant Human Hyaluronidase; Amivantamab/Recombinant Human Hyaluronidase; Amivantamab-Recombinant Human Hyaluronidase;
NCIt definition : A co-formulation composed of amivantamab, a human bispecific antibody targeting both
epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR;
c-Met), and a recombinant form of human hyaluronidase, with potential antineoplastic
activity. Upon subcutaneous administration of amivantamab and recombinant human hyaluronidase,
the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous
tissue. This increases the permeability of the subcutaneous tissue and enhances the
absorption of amivantamab into the systemic circulation. In turn, amivantamab simultaneously
targets and binds to wild-type or certain mutant forms of both EGFR and c-Met expressed
on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation
of both EGFR- and c-Met-mediated signaling pathways. In addition, binding results
in receptor degradation, which further inhibits EGFR- and c-Met-mediated signaling.
Amivantamab also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether,
this results in the inhibition of tumor cell proliferation. When administered subcutaneously,
hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered
drugs. EGFR and c-Met, upregulated or mutated in a variety of tumor cell types, play
key roles in tumor cell proliferation.;
NCI Metathesaurus CUI : CL1905618;
Origin ID : C192097;
UMLS CUI : C5784894;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
